Lisa Bodei
Memorial Sloan Kettering Cancer Center
Internal medicineRadiologyEndocrinologyPathologyOncologyProgressive diseaseNeuroendocrine tumorsDiseaseLiquid biopsyProstate cancerOctreotideNuclear medicineRadionuclide therapyPeptide receptorIn patientCancer researchClinical trialMedicineBiomarker (medicine)Chromogranin ASomatostatin receptorGastroenterology
Publications 123
#1Irvin M. Modlin (Yale University)H-Index: 81
Last. Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
view all 11 authors...
Background null Biomarkers are key tools in cancer management. In neuroendocrine tumors (NETs), Chromogranin A (CgA) was considered acceptable as a biomarker. We compared the clinical efficacy of a multigenomic blood biomarker (NETest) to CgA over a 5-year period. null null null Patients and methods null An observational, prospective, cross-sectional, multicenter, multinational, comparative cohort assessment. Cohort 1: NETest evaluation in NETs (n = 1684) and cancers, benign diseases, controls (...
#1Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
#2Mark KiddH-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 3 authors...
Abstract null null The recent development of peptide receptor radionuclide therapy (PRRT) into an accepted treatment modality allows for consideration of what needs to be undertaken to move beyond the siege warfare concept of tumor therapy. This chapter therefore seeks to address and resolve the limitations of the “huff and puff” theory of tumor destruction by critically applying the concepts and knowledge of radionuclide therapy. It therefore discusses the advantages of PRRT without ignoring it...
#1Andrew M. ScottH-Index: 87
#2Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
#1Jonathan StrosbergH-Index: 12
#2Martyn Caplin (Royal Free Hospital)H-Index: 71
Last. Marianne Pavel (FAU: University of Erlangen-Nuremberg)H-Index: 52
view all 19 authors...
#1Sonya Youngju Park (St Mary's Hospital)
Last. Erik Mittra (OHSU: Oregon Health & Science University)H-Index: 5
view all 10 authors...
A new era of precision diagnostics and therapy for patients with neuroendocrine neoplasms began with the approval of somatostatin receptor (SSTR) radiopharmaceuticals for positron emission tomography (PET) imaging followed by peptide receptor radionuclide therapy (PRRT). With the transition from SSTR-based gamma scintigraphy to PET, the higher sensitivity of the latter raised questions regarding the direct application of the planar scintigraphy-based Krenning score for PRRT eligibility. Also, to...
Abstract Biomarkers that are secretory monoanalyte products of GEP (gastro-entero-pancreatic) and BP (broncho-pulmonary) or lung NETs (neuroendocrine tumors) have significant limitations in clinical utility. The assessment of secretory activity provides little information in regard to tumor biology. Furthermore, ∼50% of NETs have measurable secretory products. Molecular genomic identification in blood (NETest liquid biopsy) of the regulators of tumor biology provide multianalyte, real-time asses...
#1Irvin M. Modlin (Yale University)H-Index: 81
#2Mark KiddH-Index: 66
Last. Alexandra KitzH-Index: 2
view all 17 authors...
Introduction Surgery is the only cure for neuroendocrine tumors (NETs), with R0 resection being critical for successful tumor removal. Early detection of residual disease is key for optimal management, but both imaging and current biomarkers are ineffective post-surgery. NETest, a multigene blood biomarker, identifies NETs with >90% accuracy. We hypothesized that surgery would decrease NETest levels and that elevated scores post-surgery would predict recurrence. Methods This was a multicenter ev...
3 CitationsSource
78 null Introduction: null null Peptide receptor radionuclide therapy (PRRT) is effective in neuroendocrine tumor (NET) management but there are limited tools for monitoring (RECIST) and prediction of tumor response, and for the delineation of side-effects. Accurate monitoring of tumor response is constrained by post-PRRT imaging limitations, and there are no effective blood-genomic assays for hematologic toxicity. We utilized three independent blood-based gene expression assays: a 51-marker gen...
#1Kelvin Hong (Johns Hopkins University)H-Index: 29
#2Olaguoke Akinwande (WashU: Washington University in St. Louis)H-Index: 8
Last. Clayton Trimmer (Baylor University Medical Center)H-Index: 1
view all 18 authors...
PURPOSE The American College of Radiology (ACR), American Brachytherapy Society (ABS), American College of Nuclear Medicine (ACNM), American Society for Radiation Oncology (ASTRO), Society of Interventional Radiology (SIR), and Society of Nuclear Medicine and Molecular Imaging (SNMMI) have jointly developed a practice parameter on selective internal radiation therapy (SIRT) or radioembolization for treatment of liver malignancies. Radioembolization is the embolization of the hepatic arterial sup...
2 CitationsSource